I trust the board knows when is the best time to approach big pharma and we have a guidance that this process will be later this calendar year. Just to have a conversation here I am just wondering if we will have enough info from the trials that have been kicked off or whether it will be a bit early to approach big pharma? Would we be in a bit better to start the big pharma discussions around mid-2022?
Also from a MC perspective, do we want to approach big pharma after we are say around $2Bn (SP around $14) so we could suggest decent multiples of the MC?
Again, I know we have an excellent board M&A / deal credentials but just while we are waiting for further news we could have a fireside/ lockdown chat
RAC Primer, page-465
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.000(0.00%) |
Mkt cap ! $281.1M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.66 | $1.61 | $117.0K | 71.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12252 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 900 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |